XML 39 R21.htm IDEA: XBRL DOCUMENT
v3.25.4

Employee Benefit Plans | 12 Months Ended
--- | ---
Dec. 31, 2025
Employee Benefit Plans [Abstract] |
Employee Benefit Plans | Employee Benefit Plans 401(k) Plan The Company has a defined contribution plan covering all eligible employees. Under the plan, employees may contribute up to 90 percent of their eligible annual compensation with the Company making matching contributions on up to 5 percent of eligible employee wages. The Company recognized expense under this plan of $32.3 million, $28.9 million, and $25.5 million for the years ended December 31, 2025, 2024 and 2023, respectively. Share-based employee compensation The Company reserved 2,000,000 shares of common stock for the Company to grant stock options, restricted stock, cash-settled stock appreciation rights ("SARs") and other stock-based awards to certain officers, directors and employees of the Company under the 2022 Long-Term Incentive Plan (the "2022 Plan"). The 2022 Plan is administered by the compensation committee of the Board of Directors. In 2025, the Board and stockholders approved an amendment to the 2022 Plan to authorize an additional 1,000,000 shares for issuance under the Plan, which increased restricted-stock capacity by 500,000 shares pursuant to the Plan's fungible ratio. Employee Stock Purchase Plan The Company reserved 1,000,000 shares of common stock for employee purchases under the 2014 Employee Stock Purchase Plan ("ESPP"). The 2014 ESPP was extended for an additional ten years until October 2034 through an amendment and restatement of the ESPP ratified at the Company's 2024 annual meeting of stockholders. Shares are purchased semi-annually, at a discount, based on the market value at period-end. Employees may contribute up to 25 percent of their base pay per offering period, not to exceed $25,000 each calendar year, for the purchase of common stock. The ESPP is a compensatory plan under applicable accounting guidance and results in the recognition of compensation expense. The following table provides information about the Company’s ESPP activity during 2025, 2024, and 2023:
Year Ended |  | Total number of shares purchased in year |  | Average price paid per share |  | Weighted-average fair value of discount under the ESPP (1)
December 31, 2023 |  | 99,802 |  |  | $ | 85.27 |  |  | $ | 14.44 |
December 31, 2024 |  | 155,101 |  |  | $ | 50.82 |  |  | $ | 8.84 |
December 31, 2025 |  | 180,437 |  |  | $ | 46.37 |  |  | $ | 7.90 |
(1) The weighted-average fair value of the discount under the ESPP granted is equal to a percentage discount from the market value of the common stock at the end of each semi-annual purchase period. 15 percent is the maximum allowable discount under the ESPP and was the discount percentage in effect in each of 2025, 2024 and 2023. Share-based compensation expense For the years ended December 31, 2025, 2024 and 2023, the Company recorded expense of $14.5 million, $24.0 million and $31.5 million, respectively, related to share-based compensation, including restricted stock awards, phantom stock awards, and the ESPP. Forfeiture rates are estimated at the time of grant based on historical actuals for similar grants and are reconciled to actuals over the vesting period. Restricted stock awards The closing price of the Company's stock on the date of grant is used as the fair value for the issuance of restricted stock. Most of the Company's non-vested restricted stock awards, subject generally to the individual's continued employment or service, are subject to a three-year graded vesting schedule. A summary of the status of non-vested restricted stock grants during the y ears ended December 31, 2025, 2024 and 2023 is presented below:
| Shares |  | Weighted Average Grant Date Fair Value Per Share
Non-vested at December 31, 2022 | 429,868 |  |  | $ | 109.33 |
Granted | 567,004 |  |  | 93.57 |
Vested | (238,020) |  |  | 119.00 |
Forfeited | (151,459) |  |  | 94.07 |
Non-vested at December 31, 2023 | 607,393 |  |  | $ | 94.64 |
Granted | 223,825 |  |  | 51.12 |
Vested | (321,281) |  |  | 92.24 |
Forfeited | (145,203) |  |  | 92.91 |
Non-vested at December 31, 2024 | 364,734 |  |  | $ | 70.73 |
Granted | 7,672 |  |  | 65.45 |
Vested | (172,176) |  |  | 74.60 |
Forfeited | (28,989) |  |  | 64.73 |
Non-vested at December 31, 2025 | 171,241 |  |  | $ | 67.61 |
The total grant date fair value of restricted stock that vested during the years ended December 31, 2025, 2024 and 2023 was $12.8 million, $29.6 million and $28.3 million, respectively. Unrecognized compensation cost was $8.1 million as of December 31, 2025 for unvested restricted stock expected to be recognized over a weighted-average period of 1.46 years. Phantom stock awards In 2024, the Company granted phantom stock awards ("PSAs") to certain employees. The value of one PSA share is equal to the value of one share of the Company's common stock, and each grant is subject to a three-year graded vesting schedule. The awards are settled in cash at vesting, with compensation costs recognized over the vesting period and adjusted to market value at each period end. As of December 31, 2025, share-based compensation liability related to PSAs was $0.6 million, which is included in accrued liabilities in the Company's consolidated balance sheet. A summary of the status of non-vested PSA grants during the y ear ended December 31, 2025, is presented below. No PSAs were granted prior to 2024.
| Phantom Stock Awards |  | Weighted Average Fair Value Per Share(1)
Non-vested at December 31, 2023 | — |  |  | — |
Granted | 125,121 |  |  | $ | 46.15 |
Vested | — |  |  | — |
Forfeited | (812) |  |  | 46.15 |
Non-vested at December 31, 2024 | 124,309 |  |  | $ | 94.12 |
Granted | — |  |  | $ | — |
Vested | (63,180) |  |  | 46.15 |
Forfeited | (12,878) |  |  | 46.15 |
Non-vested at December 31, 2025 | 48,251 |  |  | $ | 85.27 |
(1) Reflects grant date fair value, except for awards outstanding at December 31, which reflects fair value at that date. Unrecognized compensation cost was $3.0 million as of December 31, 2025 for unvested phantom stock awards expected to be recognized over a weighted-average period of 1.23 years.

X
- Definition Employee Benefit Plans [Abstract] + References No definition available. + Details
Name: | algt_EmployeeBenefitPlansAbstract
Namespace Prefix: | algt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/712/tableOfContent Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContent Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_CompensationAndEmployeeBenefitPlansTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration